However, despite its short serum half-life of less than 1 hour, likely due xto its 50–60 kDa size and the consequent rapid renal clearance, T22d35 was able to reverse the “non-T-cell-inflamed” tumor phenotype (28), implying that neutralization of TGF-β by T22d35 can overcome the immunosuppressive tumor microenvironment. The gene discussed is TGFB1; the disease is neoplasm.